Preview

Научно-практическая ревматология

Расширенный поиск

Влияние терапии генно-инженерными биологическими препаратами на субпопуляции В-лимфоцитов при ревматических заболеваниях: новые данные

https://doi.org/10.14412/1995-4484-2015-78-83

Полный текст:

Аннотация

Рассматриваются механизмы действия генно-инженерных биологических препаратов и их влияние на суб-популяции В-лимфоцитов периферической крови пациентов с системной красной волчанкой и ревматоидным артритом.

Об авторах

Е. В Супоницкая
ФГБНУ Научно- исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия 115522 Москва, Каширское шоссе, 34А
Россия

научный сотрудник лаборатории клинической иммунологии и молекулярной биологии ревматических заболеваний ФГБНУ НИИР им. В.А. Насоновой, канд. мед. наук 



Е. Н. Александрова
ФГБНУ Научно- исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия 115522 Москва, Каширское шоссе, 34А
Россия

заведующая лабораторией клинической иммунологии и молекулярной биологии ревматических заболеваний ФГБНУ НИИР им. В.А. Насоновой, докт. мед. наук 



А. П. Алексанкин
ФГБНУ Научно- исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия 115522 Москва, Каширское шоссе, 34А
Россия

младший научный сотрудник лаборатории клинической иммунологии
и молекулярной биологии ревматических заболеваний ФГБНУ НИИР
им. В.А. Насоновой, канд. биол. наук 



Е. Л. Насонов
ФГБНУ Научно- исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия 115522 Москва, Каширское шоссе, 34А
Россия

директор ФГБНУ НИИР им. В.А. Насоновой, академик РАН, докт. мед. наук, профессор 



Список литературы

1. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford). 2001;40(2):205–11. DOI: 10.1093/rheumatology/40.2.205

2. Kim HJ, Berek C. B cells in rheumatoid arthritis. Arthritis Res. 2000;2(2):126–31. DOI: 10.1186/ar77

3. Metlay JP, Pure E, Steinman RM. Control of the immune response at the level of antigen-presenting cells: a comparison of the function of dendritic cells and B lymphocytes. Adv Immunol. 1989;47:45–116. DOI: 10.1016/S0065-2776(08)60662-8

4. Takemura S, Klimiuk PA, Braun A, et al. T cell activation in rheumatoid synovium is B cell dependent. J Immunol. 2001;167(8):4710–18. DOI: 10.4049/jimmunol.167.8.4710

5. Насонов ЕЛ. Применение ритуксимаба при ревматоидном артрите. Научно-практическая ревматология. 2009;(Прил. 1):3–22 [Nasonov EL. The use of rituximab in rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2009;(Suppl 1):3–22 (In Russ.)].

6. Samuels J, Ng YS, Coupillaud C, et al. Impaired early B cell tolerance in patients with rheumatoid arthritis. J Exp Med. 2005;201(10):1659–67. DOI: 10.1084/jem.20042321

7. Anolik JH, Looney RJ, Lund FE, et al. Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol Res. 2009;(2–3):144–58. DOI: 10.1007/s12026-009-8096-7

8. Hostmann A, Jacobi AM, Mei H, et al. Peripheral B cell abnormalities and disease activity in systemic lupus erythematosus. Lupus. 2008;17(12):1064–9. DOI: 10.1177/0961203308095138

9. Lindenau S, Scholze S, Odendahl M, et al. Aberrant activation of B cells in patients with rheumatoid arthritis. Ann N Y Acad Sci. 2003;987:246–8. DOI: 10.1111/j.1749-6632.2003.tb06055.x

10. Henneken M, Dö rner T, Burmester GR, Berek C. Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther. 2005;7(5):R1001–13. DOI: 10.1186/ar1776

11. Dö rner T, Jacobi AM, Lipsky PE. B cells in autoimmunity. Arthritis Res Ther. 2009;11(5):247. DOI: 10.1186/ar2780

12. Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010;47(2):115–23. DOI: 10.1053/j.seminhematol.2010.01.011

13. Valentine MA, Meier KE, Rossie S, Clark EA. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C. J Biol Chem. 1989;264(19):11282–7.

14. Einfeld DA, Brown JP, Valentine MA, et al. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J. 1988;7(3):711–7.

15. Stashenko P, Nadler LM, Hardy R, et al. Characterization of a human B lymphocyte-specific antigen. J Immunol. 1980;125(4):1678–85.

16. Tedder TF, Boyd AW, Freedman AS, et al. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol. 1985;135(2):973–9.

17. Roll P, Dorner T, Tony HP. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum. 2008;58(6):1566–75. DOI: 10.1002/art.23473

18. Nakou M, Katsikas G, Sidiropoulos P, et al. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther. 2009;11(4):R131. DOI: 10.1186/ar2798

19. Cambridge G, Leandro MJ, Edwards JC, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 2003;48(8):2146–54. DOI: 10.1002/art.11181

20. Александрова ЕН, Новиков АА, Соловьев СК и др. В-клетки при аутоиммунных ревматических заболеваниях. В кн.: Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Под ред. ЕЛ Насонова. Москва: ИМА-Пресс; 2012. С. 8–46 [Aleksandrova EN, Novikov AA, Solov'ev SK, et al. B cells in autoimmune rheumatic diseases. In: Anti-B-kletochnaya terapiya v revmatologii: fokus na rituksimab [Anti-B-cell therapy in rheumatology: Focus on rituximab]. Nasonov EL, editor. Moscow: IMA-Press; 2012. P. 8–46.

21. Anolik JH, Barnard J, Owen T, et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum. 2007;56(9):3044–56. DOI: 10.1002/art.22810

22. Silverman GJ, Boyle DL. Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti-CD20 therapy: the B-cell roadblock hypothesis. Immunol Rev. 2008;223:175–85. DOI: 10.1111/j.1600-065X.2008.00627.x

23. Amu S, Tarkowski A, Dö rner T, et al. The human immunomodulatory CD25+ B cell population belongs to the memory B cell pool. Scand J Immunol. 2007;66(1):77–86. DOI: 10.1111/j.13653083.2007.01946.x

24. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-celltargeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350(25):2572–81. DOI: 10.1056/NEJMoa032534

25. Quartuccio L, Fabris M, Salvin S, et al. Rheumatoid factor positivity rather then ant-CCP positiviry, a lower disability and a lower number anti-TNF agents failed are associated with response to Rituximab in rheumatoid arthritis. Rheumatology (Oxford). 2009;48(12):1557–9. DOI: 10.1093/rheumatology/kep314

26. Cornec D, Avouac J, Youinou P, Saraux A. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun Rev. 2009;8(6):515–9. DOI: 10.1016/j.autrev.2009.01.007

27. Cambridge G, Leandro MG, Teodorescu M. B cell depletion therapy in systemic lupus erythematosus. Effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum. 2006;54(11):3612–22. DOI: 10.1002/art.22211

28. Erre GL, Pardini S, Faedda R, Passiu G. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus. 2008;17(1):50–5. DOI: 10.1177/0961203307085251

29. Yoannou Y, Lambrianides A, Cambridge G, et al. B cell depletion therapy for patients with systemic lupus erythaematosus results in a significant drop in anticardiolipin antibody titres. Ann Rheum Dis. 2008;67(3):425–6. DOI: 10.1136/ard.2007.078402

30. Sanz I, Wei C, Lee FE, Anolik J. Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol. 2008;20(1):67–82. DOI: 10.1016/j.smim.2007.12.006

31. Silverman GJ, Pelzek A. Rheumatoid arthritis clinical benefits from Abatacept, cytokine blockers, and Rituximab are all linked to modulation of memory B cell responses. J Rheumatol. 2014;41(5):825–8. DOI: 10.3899/jrheum.140022

32. Modi S, Soejima M, Levesque MC. The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses. Clin Exp Immunol. 2013;173(1):8–17. DOI: 10.1111/cei.12114

33. Sellam J, Rouanet S, Taoufic Y, et al. Predictive factors of response to rituximab in rheumatoid arthritis with inadequate response or intolerance to anti-TNF: data from SMART trial. Ann Rheum Dis. 2010;69(Suppl 3):68 [OP0050].

34. Souto-Carneiro MM, Mahadevan V, Takada K, et al. Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor. Arthritis Res Ther. 2009(3);11:R84. DOI: 10.1186/ar2718

35. Catalan D, Aravena O, Sabugo F, et al. B cells from rheumatoid arthritis patients show important alterations in the expression of CD86 and FcgammaRIIb, which are modulated by anti-tumor necrosis factor therapy. Arthritis Res Ther. 2010;12(2):R68. DOI: 10.1186/ar2985

36. Menard L, Samuels J, Ng YS, Meffre E. Inflammation-independent defective early B cell tolerance checkpoints in rheumatoid arthritis. Arthritis Rheum. 2011;63(5):1237–45. DOI: 10.1002/art.30164

37. Anolik JH, Ravikumar R, Barnard J, et al. Anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J Immunol. 2008;180(2):688–92. DOI: 10.4049/jimmunol.180.2.688

38. Glaesener S, Qu

39. Daien CI, Gailhac S, Mura T, et al. High levels of memory B cells are associated with response to a first tumor necrosis factor inhibitor in patients with rheumatoid arthritis in a longitudinal prospective study. Arthr Res Ther. 2014;16(2):R95. DOI: 10.1186/ar4543

40. Fonseca JE, Santos MJ, Canhao H, Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev. 2009;8(7):538–42. DOI: 10.1016/j.autrev.2009.01.012

41. Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis. 1993;52(3):232–4. DOI: 10.1136/ard.52.3.232

42. Houssiau FA, Devogelaer JP, van Damme J, et al. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 1988;31(6):784–8. DOI: 10.1002/art.1780310614

43. Kotake S, Sato K, Kim KJ, et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res. 1996;11(1):88–95. DOI: 10.1002/jbmr.5650110113

44. Roll P, Muhammad K, Schumann M, et al. In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment. Arthritis Rheum. 2011;63(5):1255–64. DOI: 10.1002/art.30242

45. Mahmood Z, Muhammad Kh, Roll P, et al. IL-6 receptor inhibition by Tocilizumab modulates double negative (CD19+IgDCD27-) B Cells in RA. [abstract]. Arthritis Rheum. 2012;64(10 Suppl):S754.

46. Shirota Y, Yarboro C, Fischer R, et al. Impact of anti-interleukin6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann Rheum Dis. 2013;72(1):118–28. DOI: 10.1136/annrheumdis-2012-201310

47. Conaghan PG, Durez P, Alten RE, et al. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. Ann Rheum Dis. 2013;72(8):1287–94. DOI: 10.1136/annrheumdis-2012201611

48. Van Kooten C, Banchereau J. CD40-CD40 ligand. J Leuk Biol. 2000;67(1):2–17.

49. Cutolo M, Nadler SG. Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis. Autoimmun Rev. 2013;12(7):758–67. DOI: 10.1016/j.autrev.2013.01.001

50. Scarsi M, Paolini L, Ricotta D, et al. Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis. J Rheumatol. 2014;41(4):666–72. DOI: 10.3899/jrheum.130905

51. Gottenberg JE, Ravaud P, Cantagrel A, et al. Positivity for anticyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registry. Ann Rheum Dis. 2012;71(11):1815–9. DOI: 10.1136/annrheumdis-2011-201109

52. Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol. 2003;21:231–64. DOI: 10.1146/annurev.immunol.21.120601.141152

53. Scholz JL, Cancro MP. Resolve, revise, and relax: the 3 Rs of B cell repertoire adjustment. Immunology Lett. 2012;143(1):2–8. DOI: 10.1016/j.imlet.2012.01.014

54. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61(9):1168–78. DOI: 10.1002/art.24699

55. Tak PP, Thurlings RM, Rossier C, et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, doubleblind, placebo-controlled, dose-escalating, singleand repeateddose study. Arthritis Rheum. 2008;58(1):61–72. DOI: 10.1002/art.23178

56. Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in the patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64(7):2328–37. DOI: 10.1002/art.34400

57. Manzi S, Sаnchez-Guerrero J, Merrill JT, et al. BLISS-52 and BLISS-76 Study Groups: Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71(11):1833–8. DOI: 10.1136/annrheumdis-2011-200831

58. Navarra SV, Guzmаn RM, Gallacher AE, et al. BLISS-52 Study Group: Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721–31. DOI: 10.1016/S0140-6736(10)61354-2

59. Van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012;71(8):1343–9. DOI: 10.1136/annrheumdis-2011-200937

60. Genovese MC, Kinnman N, de La Bourdonnaye G, et al. Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum. 2011;63(7):1793–803. DOI: 10.1002/art.30373

61. Genovese M, Silverman J, Emery P, et al. Efficacy and safety of subcutaneous administration of tabalumab, an anti-B cell activating factor monoclonal antibody, in rheumatoid arthritis: results from a phase 3 multicenter, randomized, double-blind study [abstract]. Arthritis Rheum. 2013;65(10 Suppl):S733.

62. Wang Sh-P, Iwata Sh, Nakayamada Sh, et al. Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro. Ann Rheum Dis. 2014 Dec;73(12):2213–5. DOI:10.1136/annrheumdis-2014205615

63. Tanaka Y, Yamaoka K. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical. Mod Rheumatol. 2013;23(3):415–24. DOI: 10.1007/s10165-012-0799-2

64. Tanaka Y, Maeshima Y, Yamaoka K. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis. Ann Rheum Dis. 2012;71(Suppl 2):i70–4. DOI: 10.1136/annrheumdis-2011200595


Для цитирования:


Супоницкая Е.В., Александрова Е.Н., Алексанкин А.П., Насонов Е.Л. Влияние терапии генно-инженерными биологическими препаратами на субпопуляции В-лимфоцитов при ревматических заболеваниях: новые данные. Научно-практическая ревматология. 2015;53(1):78-83. https://doi.org/10.14412/1995-4484-2015-78-83

For citation:


Suponitskaya E.V., Aleksandrova E.N., Aleksankin A.P., Nasonov E.L. IMPACT OF THERAPY WITH BIOLOGICAL AGENTS ON B-LYMPHOCYTE SUBPOPULATIONS IN RHEUMATIC DISEASES: NEW EVIDENCE. Rheumatology Science and Practice. 2015;53(1):78-83. (In Russ.) https://doi.org/10.14412/1995-4484-2015-78-83

Просмотров: 467


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)